(Reuters) - French drugmaker Sanofi-Aventis hopes to reach a takeover deal that would value U.S. target Genzyme (NasdaqGS:GENZ - News) at around $76 per share, or some $20 billion, the French daily newspaper Le Figaro said on Friday.
(Reuters) - French drugmaker Sanofi-Aventis hopes to reach a takeover deal that would value U.S. target Genzyme (NasdaqGS:GENZ - News) at around $76 per share, or some $20 billion, the French daily newspaper Le Figaro said on Friday.
